When was Hawkeye Bio founded?

Hawkeye Bio was founded in 2018.

Where is Hawkeye Bio located?

Hawkeye Bio is headquartered in Westlake Village, United States.

How many employees does Hawkeye Bio have?

As of Jul 01, 2024, the latest employee count at Hawkeye Bio is 6.

Is Hawkeye Bio a funded company?

Hawkeye Bio is a funded company, having raised a total of $***** in its 1st and only funding round.

Where does Hawkeye Bio rank among its competitors?

Hawkeye Bio ranks 17th amongst 46 active competitors, of which 18 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Owlstone Medical, which secured $49.1M in Oct, 2025.

Who are the top competitors of Hawkeye Bio?

Hawkeye Bio's top competitors include Biodesix, Owlstone Medical and ONCOHOST. Among them, Owlstone Medical secured the most recent funding round in October, 2025.

Hawkeye Bio - 2026 Company Profile, Team, Funding & Competitors

Hawkeye Bio is a funded company based in Westlake Village (United States), founded in 2018 by Paul Dempsey and Andre de Fusco. It operates as a Provider of solution for non-invasive detection of the early stage of lung cancer. The company has 46 active competitors, including 18 funded and 9 that have exited. Its top competitors include companies like Biodesix, Owlstone Medical and ONCOHOST.

Company Details

HawkeyeBio provides the solution for non-invasive detection of the early stage of lung cancer. The company offers its flagship product Hawkeye based on Exhaled Breath Condensate (EBC) which is very sensitive to detect the early stage of lung cancer especially in the case of second-hand smokers, radon, workplace carcinogens, and pollution exposure individuals.

Website: www.hawkeyebio.com/
Social
Email ID: *****@hawkeyebio.com

Key Metrics

Founded Year

2018

Location

Westlake Village, United States

Stage

Funding Raised

Investors

NJF Capital

Ranked

17^th among 46 active competitors

Employee Count

6 as on Jul 01, 2024

Similar Companies

Biodesix & 57 more

View Hawkeye Bio's full profile

Hawkeye Bio is a funded company. Hawkeye Bio has 1 institutional investor.

View details of Hawkeye Bio's funding rounds and investors

The founders of Hawkeye Bio are Paul Dempsey and Andre de Fusco.

Here are the details of Hawkeye Bio's key team members:

Paul Dempsey: Co-Founder & CSO of Hawkeye Bio.
Andre de Fusco: Co-Founder & CEO of Hawkeye Bio.
Contact Info: 1 email address

View details of Hawkeye Bio's Founder profiles and Board Members

Hawkeye Bio's employee count trend

Hawkeye Bio has 6 employees as of Jul 24. Here is Hawkeye Bio's employee count trend over the years:

Uncover Hawkeye Bio's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Hawkeye Bio include Biodesix, Owlstone Medical and ONCOHOST. Here is the list of Top 10 competitors of Hawkeye Bio, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Biodesix 2005, Boulder (United States), Public	Developer of diagnostics assays for the detection of cancer	$200M	Lincoln Park Capital, Perceptive Advisors ... & 1 others	75/100
2nd	Owlstone Medical 2004, Cambridge (United Kingdom), Series E	Developer of non-invasive breath-based diagnostics for cancer and infectious diseases	$167M	Horizons Ventures, Aviva & 65 others	65/100
3rd	ONCOHOST 2017, Binyamina Giv at Ada (Israel), Series C	AI-based oncology therapy plan solution for professionals	$43M	OurCrowd, ALIVE & 5 others	61/100
4th	Body Vision Medical 2014, Waltham (United States), Series C	Developer of AI-driven imaging system for lung cancer diagnostic intervention	$28.5M	AA Sons, ADIP & 6 others	60/100
5th	OncoCyte 2009, Irvine (United States), Public	Developer of non-invasive diagnostic tests solutions for the treatment of cancer	$15.3M	Geode Capital, Connor, Clark & Lunn Financial Group ... & 5 others	60/100
6th	Oxford Cancer Analytics 2018, Oxford (United Kingdom), Series A	Provider of a platform for detection of lung cancer	$16.5M	Eka Ventures, Cross Border Impact Ventures ... & 12 others	58/100
7th	LEADOPTIK 2020, Milpitas (United States), Seed	Provider of AI-powered optical processors	$11.2M	HAX, MetaVC Partners & 7 others	56/100
8th	Mursla 2017, London (United Kingdom), Seed	Provider of diagnostic device for cancer detection	$547K	Future Fund, TA Ventures & 26 others	55/100
9th	Amadix 2010, Madrid (Spain), Series A	Provider of diagnostic tools to support personalized cancer treatment	$6.87M	Alentia, Inveready & 8 others	54/100
10th	Biofidelity 2002, Cambridge (United Kingdom), Series B	Developer of a molecular diagnostic assay for the detection of target DNA sequences	$60M	Octopus Ventures, Longwall Venture Partners ... & 4 others	50/100
17th	Hawkeye Bio 2018, Westlake Village (United States), Funding Raised	Provider of solution for non-invasive detection of the early stage of lung cancer	-	NJF Capital	42/100